Improving Outcomes in Cardiac Arrest With Inhaled Nitric Oxide


Sudden cardiac arrest (CA) is a leading cause of death worldwide. CA claims the lives of an estimated 300,000 Americans each year. Despite advances in cardiopulmonary resuscitation (CPR) methods, only approximately 10% of adults with CA survive to hospital discharge, and up to 60% of survivors have moderate to severe cognitive deficits 3 months after resuscitation. Most of the immediate and post-CA mortality and morbidity are caused by global ischemic brain injury. The goal of this grant application is to test the hypothesis that resuscitation from cardiac arrest can be improved by improving cerebral oxygenation through inhalation of nitric oxide. This strategy will also improve the chances of return of spontaneous circulation (ROSC), improve short-term survival and neurologic outcome.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2020


  • Drug: inhaled nitric oxide
    • Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest

Arms, Groups and Cohorts

  • Experimental: inhaled nitric oxide
    • Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.

Clinical Trial Outcome Measures

Primary Measures

  • Rate of return of spontanueous circulation (ROSC)
    • Time Frame: 1 day
    • The primary outcome measure is to evaluate rates of return of spontaneous circulation (ROSC) from in hospital cardiac arrest patient who receive inhaled nitric oxide
  • Change in cerebral oxygenation (rSO2)
    • Time Frame: 1 day
    • The outcomes measure is to evaluate change in the concentration of cerebral oxygenation measured by Near-infrared spectroscopy before and after the administration of inhaled nitric oxide

Secondary Measures

  • Neurologic outcomes at hospital discharge
    • Time Frame: upto 24 weeks
    • Patient who suffered in hospital cardiac arrest has variable neurologic outcomes. This will be evaluated with Glasgow outcome scale (GOS). This score ranges from 1 to 5 where GOS 1-3 is considered unfavourable neurologic outcomes and GOS 4-5 are considered favourable neurologic outcomes.
  • short term survival
    • Time Frame: upto 24 weeks
    • Short term survival will include survival from hospital to discharge

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18 years and above

2. In-hospital cardiac arrest as defined by cessation of heartbeat

3. Presence of Endotracheal Tube

Exclusion Criteria

1. Age below 18 years

2. Absence of Endotracheal Tube

3. Patients with out-of-hospital cardiac arrest

4. Patients involved in trauma and/or patients in the SICU or CTICU

5. Preexisting intra-cerebral lesions such as any head injury (old or new), brain hematoma, cerebral hemorrhage or known frontal lobe disorders such as tumors

6. Any patient with a terminal condition that cannot be treated (specifically any terminal malignancy, end stage lung fibrosis, chronic heart failure with an ejection fraction <20%)

7. Patients with do not resuscitate and/or do not intubate (DNR/DNI) status

8. Therapeutic window has passed

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Stony Brook University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jignesh Patel, Associate Professor of Medicine – Stony Brook University
  • Overall Official(s)
    • Jignesh K Patel, MD, Principal Investigator, Stony Brook University
  • Overall Contact(s)
    • Jignesh Patel, MD,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.